SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma

Documenti analoghi

• P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
  di: Chiara Rusconi, et al.
  Pubblicazione: (2022-10-01)
• P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
  di: Chiara Rusconi, et al.
  Pubblicazione: (2023-08-01)
• P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
  di: Chiara Rusconi, et al.
  Pubblicazione: (2022-10-01)
• Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections
  di: Paolo Corradini, et al.
  Pubblicazione: (2020-06-01)
• Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease
  di: Otsuji N, et al.
  Pubblicazione: (2024-06-01)